Meetings - The ASCO Post

Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent ne...

Leukemia

By Caroline Helwick / August 25, 2024 / 2024 Pan Pacific Lymphoma Conference

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored b...

Lymphoma

By Caroline Helwick / September 10, 2024 / 2024 Pan Pacific Lymphoma Conference

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bel...

2024 Pan Pacific Lymphoma Conference

BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

IASLC: AI Method Transforms Gene Mutation Prediction in Lung Cancer

Treating TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC

IASLC: Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Youth E Cigarette Use May Have Declined to Lowest Level in a Decade

High Proportion of US Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late Stage Diagnoses Continue to Rise